The FDA has concluded that type 2 diabetes medicine Canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.
Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study with the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with Canagliflozin (Invokana, Invokamet, Invokamet XR) compared to patients treated with placebo, which is an inactive treatment.
Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. See the FDA Drug Safety Communication for additional information, including a data summary.
If you have had an amputation and took the type 2 diabetes medicine Canagliflozin (Invokana, Invokamet, Invokamet XR) then learn your rights by calling toll free 855-264-2833. Lawyers are standing by to educate you on your rights.